0 Items
Toll Free (US) - +1-866-598-1553
sales@precisionbusinessinsights.com
Breast Cancer Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

Breast Cancer Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00 – $ 8,900.00

Breast Cancer Treatment Market by Drug Class (Anthracyclines, Antimetabolites, Epothilones, Taxanes, Alkylating agents, Hormonal therapy, Aromatase inhibitors, Selective Oestrogen-receptor modulators), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)

 

 

Request Sample Request Methodology
Request Sample Read More
$ PRICE - $ 3,000.00 – $ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00 – $ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: , Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Report

Description

Breast Cancer Treatment market size was valued at US$ 19.5 Billion in 2020 and is expected to grow US$ 33.20 Billion by 2027 at a CAGR of 7.9% during the forecast period. Breast cancer is the disease occurs when uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Treatment of breast cancer depends on various factors such as the type of breast cancer, the size of a tumour, stage of breast cancer and the grade of cancer cells. The breast cancer can be treated by various therapies such as radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy. The common signs and symptoms associated with breast cancer include change in the breast shape, forming of lumps in the breast, dimpling of skin, and red scaly patches on the skin. In severe conditions, bone pain, swelling of lymph nodes, problems in respiration, and yellow skin may appear. The breast cancer commonly occurs due to drinking alcohol, being female, obesity, ionizing radiation, family history and older age among others. Breast cancer is diagnosed by taking a biopsy of lump. After the diagnosis, further tests are carried to determine the cancer stage and suitable treatment for the disease. In July 2017, U.S. FDA Approved Puma Biotechnology’s Nerlynx (Neratinib) for the treatment of HER2-positive breast cancer in early stag. In July 2017, AstraZeneca received the approval from European Commission (EC) for  Faslodex (fulvestrant) for the breast cancer treatment

Breast Cancer Treatment Market

MARKET SUMMARY
-
7.9% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 7.9%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Breast Cancer Treatment Market Analysis

  • Global breast cancer treatment market is in developing stage, owing to increase in the prevalence rate of breast cancer disease. According to World Health Organization, about 2000 new cases in men and approximately 200,000 new breast cancer cases in women are diagnosed.
  • Most of the pharmaceutical companies in breast cancer treatment market are focus on research and development activities, strategic collaborations, acquisitions & mergers, and product launches for the development of their revenue in the breast cancer treatment market.
  • For instance, in March 2017, Novartis has received FDA approval for its drug kisqali (ribociclib, LEE011) used as first-line treatment for the HR+/HER2 metastatic breast cancer along with aromatase inhibitor. Similarly, In September 2013, The U.S. Food and Drug Administration granted the accelerated approval for Perjeta (pertuzumab) used in the treatment of early stage breast cancer treatment before surgery. The innovation of some innovative therapy with better success rate is expected to offer a good opportunity for breast cancer treatment market.
Market Leaders
  • AstraZeneca (U.K.)
  • GlaxoSmithKline plc (U.K.)
  • Eli Lilly and Company (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Pfizer, Inc (U.S.)
  • Sun Pharmaceutical Industries Ltd (India)
  • Actavis, Inc. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Bayer AG (Germany)
  • Teva Pharmaceutical Industries. Ltd. (Israel)
  • Puma Biotechnology, Inc. (U.S.)
  • OncoGenex Pharmaceuticals Inc. (U.S.)
Breast Cancer Treatment Market

Drivers and Restraints

The global breast cancer treatment market is expected to increase with significant CAGR due to increasing prevalence and incidence of breast cancer cases. Rising awareness about breast cancer stages and treatment, government initiatives, and improving healthcare infrastructure are driving the breast cancer treatment market. Moreover, the rise in the healthcare expenditure, increase in the diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco, and rising female population age of 65 years and above are expected to fuel the market over the forecast period.

Furthermore, increase in the investments in research and developments, development of targeted drug delivery systems, and advancement in cancer biology & pharmacology might boost the market. However, drug development challenges in developing countries, long-term side effects of drugs, high costs associated with drug development, stringent regulatory guidelines, and patent expiry of drugs might hamper the growth of the market in the forecast years.

Breast Cancer Treatment Market

North America dominates the market

Geographically, the breast cancer drugs market segmented into following regions Viz. Europe, Latin America, Middle East and Africa, Asia-Pacific, and North America. North America dominates the breast cancer treatment market mainly attributed to high prevalence of breast cancer disease, increase in female aging population, and favourable government initiatives for the treatment. Furthermore, increase in the healthcare infrastructure, favourable reimbursement policies, and high incorporation of targeted therapies also propel the breast cancer treatment market growth in North America region. Europe holds a major share in breast cancer treatment market owing to rise in the prevalence and incidence of breast cancer cases (According to World Cancer Research Fund International, nearly 1.7 million new breast cancer cases were diagnosedin 2012. In the UK itself, 53,696 new cases were diagnosed in 2013).

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East
Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015-2020) and forecast (2021-2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Breast Cancer Treatment Market Segmentation

segmentation-block-image

Drug Class

    • Anthracyclines
    • Antimetabolites
    • Epothilones
    • Taxanes
    • Alkylating agents
    • Hormonal therapy
    • Aromatase inhibitors
    • Selective Oestrogen-receptor modulators
segmentation-block-image

Distribution Channel

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
segmentation-block-image

Geography

    • North America
    • Latin Americ
    • Europe
    • Asia Pacific
    • Middle East and Africa
Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Report

Table Of Content

1. Executive Summary
2. Global Breast Cancer Treatment Market Introduction
2.1. Global Breast Cancer Treatment Market – Taxonomy
2.2. Global Breast Cancer Treatment Market –Definitions
2.2.1. By Treatment
2.2.2. By Cancer Type
2.2.3. By Distribution Channel
3. Global Breast Cancer Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Breast Cancer Treatment Market Dynamic Factors – Impact Analysis
3.6. Global Breast Cancer Treatment Market – Competition Landscape
4. Global Breast Cancer Treatment Market Analysis,2017 – 2021 and Forecast, 2022 – 2028
2.1. Global Breast Cancer Treatment Market – Taxonomy
2.1. Global Breast Cancer Treatment Market – Taxonomy
2.1. Global Breast Cancer Treatment Market – Taxonomy
5. Global Breast Cancer Treatment Market, By Treatment, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
5.1. Immunotherapy
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Chemotherapy
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Targeted Treatment
5.3.1. Abemaciclib
5.3.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.1.3. Market Opportunity Analysis
5.3.2. Ado-Trastuzumab Emtansine
5.3.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.2.3. Market Opportunity Analysis
5.3.3. Everolimus
5.3.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3.3. Market Opportunity Analysis
5.3.4. Olaparib
5.3.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.4.3. Market Opportunity Analysis
5.3.5. Palbociclib
5.3.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.5.3 Market Opportunity Analysis
5.3.6. Pertuzumab
5.3.6.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.6.3. Market Opportunity Analysis
5.3.7. Ribociclib
5.3.7.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.7.3. Market Opportunity Analysis
5.3.8. Trastuzumab
5.3.8.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.8.3. Market Opportunity Analysis
5.3.9. Others
5.3.9.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.3.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.9.3. Market Opportunity Analysis
5.4. Hormonal Treatment
5.4.1. Aromatase Inhibitors
5.4.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.1.3. Market Opportunity Analysis
5.4.2. Estrogen Receptor Downregulators (ERDs)
5.4.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.2.3. Market Opportunity Analysis
5.4.3. Selective Estrogen Receptor Modulators (SERMs)
5.4.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
5.4.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3.3. Market Opportunity Analysis
6. Global Breast Cancer Treatment Market Forecast, By Cancer Type, 2017 – 2021 and Forecast, 2020 – 2026 (Revenue, USD Mn) 
6.1. HER2+
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Hormone Receptor
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Breast Cancer Treatment Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2020 – 2026 (Revenue, USD Mn) 
7.1. Hospital
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Pharmacies
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Others
7.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
8. Global Breast Cancer Treatment Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Breast Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Region, 2022 – 2028
9. North America Breast Cancer TreatmentMarketAnalysis,2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
9.1.1. Flat Rolled
9.1.2. Immunotherapy
9.1.3. Chemotherapy
9.1.4. Targeted Treatment
9.1.4.1. Abemaciclib
9.1.4.2. Ado-Trastuzumab Emtansine
9.1.4.3. Everolimus
9.1.4.4. Trastuzumab
9.1.4.5. Ribociclib
9.1.4.6. Palbociclib
9.1.4.7. Pertuzumab
9.1.4.8. Olaparib
9.1.4.9. Others
9.1.5. Hormonal Treatment
9.1.5.1. Aromatase Inhibitors
9.1.5.2. Estrogen Receptor Downregulators (ERDs)
9.1.5.3. Selective Estrogen Receptor Modulators (SERMs)
9.2. Cancer Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. HER2+
9.2.2. Hormone Receptor
9.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.3.4. Pharmacies
9.3.5. Others
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Breast Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country, 2022 – 2028
9.6. North America Breast Cancer Treatment Market Dynamics – Trends
10. Europe Breast Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
10.1. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
10.1.1. Flat Rolled
10.1.2. Immunotherapy
10.1.3. Chemotherapy
10.1.4. Targeted Treatment
10.1.4.1. Abemaciclib
10.1.4.2. Ado-Trastuzumab Emtansine
10.1.4.3. Everolimus
10.1.4.4. Trastuzumab
10.1.4.5. Ribociclib
10.1.4.6. Palbociclib
10.1.4.7. Pertuzumab
10.1.4.8. Olaparib
10.1.4.9. Others
10.1.5. Hormonal Treatment
10.1.5.1. Aromatase Inhibitors
10.1.5.2. Estrogen Receptor Downregulators (ERDs)
10.1.5.3. Selective Estrogen Receptor Modulators (SERMs)
10.2. Cancer Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. HER2+
10.2.2. Hormone Receptor
10.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.3.4. Pharmacies
10.3.5. Others
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Breast Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country,2022 – 2028
10.6. Europe Breast Cancer Treatment Market Dynamics – Trends
11. Asia-Pacific Breast Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
11.1. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
11.1.1. Flat Rolled
11.1.2. Immunotherapy
11.1.3. Chemotherapy
11.1.4. Targeted Treatment
11.1.4.1. Abemaciclib
11.1.4.2. Ado-Trastuzumab Emtansine
11.1.4.3. Everolimus
11.1.4.4. Trastuzumab
11.1.4.5. Ribociclib
11.1.4.6. Palbociclib
11.1.4.7. Pertuzumab
11.1.4.8. Olaparib
11.1.4.9. Others
11.1.5. Hormonal Treatment
11.1.5.1. Aromatase Inhibitors
11.1.5.2. Estrogen Receptor Downregulators (ERDs)
11.1.5.3. Selective Estrogen Receptor Modulators (SERMs)
11.2. Cancer Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. HER2+
11.2.2. Hormone Receptor
11.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.3.4. Pharmacies
11.3.5. Others
11.4. Country Analysis2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Breast Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country,2022 – 2028
11.6. Asia-Pacific Breast Cancer Treatment Market Dynamics – Trends
12. Latin America Breast Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
12.1. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
12.1.1. Flat Rolled
12.1.2. Immunotherapy
12.1.3. Chemotherapy
12.1.4. Targeted Treatment
12.1.4.1. Abemaciclib
12.1.4.2. Ado-Trastuzumab Emtansine
12.1.4.3. Everolimus
12.1.4.4. Trastuzumab
12.1.4.5. Ribociclib
12.1.4.6. Palbociclib
12.1.4.7. Pertuzumab
12.1.4.8. Olaparib
12.1.4.9. Others
12.1.5. Hormonal Treatment
12.1.5.1. Aromatase Inhibitors
12.1.5.2. Estrogen Receptor Downregulators (ERDs)
12.1.5.3. Selective Estrogen Receptor Modulators (SERMs)
12.2. Cancer Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. HER2+
12.2.2. Hormone Receptor
12.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.3.4. Pharmacies
12.3.5. Others
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Breast Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country,2022 – 2028
12.6. Latin America Breast Cancer Treatment Market Dynamics – Trends
13. Middle East and Africa Breast Cancer Treatment Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
13.1. Treatment Analysis 2017 – 2021 and Forecast 2022 – 2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
13.1.1. Flat Rolled
13.1.2. Immunotherapy
13.1.3. Chemotherapy
13.1.4. Targeted Treatment
13.1.4.1. Abemaciclib
13.1.4.2. Ado-Trastuzumab Emtansine
13.1.4.3. Everolimus
13.1.4.4. Trastuzumab
13.1.4.5. Ribociclib
13.1.4.6. Palbociclib
13.1.4.7. Pertuzumab
13.1.4.8. Olaparib
13.1.4.9. Others
13.1.5. Hormonal Treatment
13.1.5.1. Aromatase Inhibitors
13.1.5.2. Estrogen Receptor Downregulators (ERDs)
13.1.5.3. Selective Estrogen Receptor Modulators (SERMs)
13.2. Cancer Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. HER2+
13.2.2. Hormone Receptor
13.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.3.4. Pharmacies
13.3.5. Others
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Breast Cancer Treatment Market – Opportunity Analysis Index, By Treatment, By Cancer Type, Distribution Channel and Country,2022 – 2028
13.6. MEA Breast Cancer Treatment Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Cancer Type& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AstraZeneca plc
14.2.2. Eisai Co. Ltd.
14.2.3. Eli Lilly and Company
14.2.4. F. Hoffmann-La Roche Ltd.
14.2.5. GlaxoSmithKline plc
14.2.6. Novartis International AG
14.2.7. Pfizer Inc.
14.2.8. Puma Biotechnology Inc.
14.2.9. Sanofi S.A.
14.2.10. Teva Pharmaceutical Industries Ltd.
15. Research Methodology
16. Key Assumptions and Acronyms
Report

Company Profile

  • AstraZeneca (U.K.)
  • GlaxoSmithKline plc (U.K.)
  • Eli Lilly and Company (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Pfizer, Inc (U.S.)
  • Sun Pharmaceutical Industries Ltd (India)
  • Actavis, Inc. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • Bayer AG (Germany)
  • Teva Pharmaceutical Industries. Ltd. (Israel)
  • Puma Biotechnology, Inc. (U.S.)
  • OncoGenex Pharmaceuticals Inc. (U.S.)

Description

Breast Cancer Treatment market size was valued at US$ 19.5 Billion in 2020 and is expected to grow US$ 33.20 Billion by 2027 at a CAGR of 7.9% during the forecast period. Breast cancer is the disease occurs when uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Treatment of breast cancer depends on various factors such as the type of breast cancer, the size of a tumour, stage of breast cancer and the grade of cancer cells. The breast cancer can be treated by various therapies such as radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy. The common signs and symptoms associated with breast cancer include change in the breast shape, forming of lumps in the breast, dimpling of skin, and red scaly patches on the skin. In severe conditions, bone pain, swelling of lymph nodes, problems in respiration, and yellow skin may appear. The breast cancer commonly occurs due to drinking alcohol, being female, obesity, ionizing radiation, family history and older age among others. Breast cancer is diagnosed by taking a biopsy of lump. After the diagnosis, further tests are carried to determine the cancer stage and suitable treatment for the disease. In July 2017, U.S. FDA Approved Puma Biotechnology’s Nerlynx (Neratinib) for the treatment of HER2-positive breast cancer in early stag. In July 2017, AstraZeneca received the approval from European Commission (EC) for  Faslodex (fulvestrant) for the breast cancer treatment

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX

QUICKLINKS
RESEARCH AREAS
PRESS RELEASE
CONTACT US
+1-866-598-1553
EMAIL
sales@precisionbusinessinsights.com
FOLLOW US
QUICK LINKS+
RESEARCH AREAS+
PRESS RELEASE+
CONTACT US+
+1-866-598-1553
sales@precisionbusinessinsights.com
FOLLOW US AT+